Erschienen in:
04.08.2022 | COVID-19 | Correspondence
Antibody responses and correlates after two and three doses of BNT162b2 COVID-19 vaccine
Erschienen in:
Infection
|
Ausgabe 2/2023
Einloggen, um Zugang zu erhalten
Excerpt
While the mRNA COVID-19 vaccines are highly effective in decreasing the risk of infection, hospitalization, and death [
1], a significant variation in the immune response among vaccine recipients has been identified. Specifically, male sex, older age, and chronic diseases have been associated with lower anti-spike antibody levels after two vaccine doses [
2,
3]. It remains elusive, however, whether such a difference in humoral immune response persists after the third vaccine dose, which is currently administered in many countries. Here, we report immunogenicity after the third dose of the BNT162b2 vaccine in relation to the correlates of that after the second dose. …